Senores Pharmaceuticals · NSE: SENORES · BSE: 544319
Q1 FY27 results · Apr–Jun 2026
Senores Pharmaceuticals reported revenue from operations of ₹180.21 crore (up 30.6% from Q1 FY26) and net profit of ₹30.45 crore (up 43.8% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 180.21 | 137.99 | +30.6% | 175.19 | +2.9% |
| Other income | 2.81 | 3.36 | −16.4% | 17.67 | −84.1% |
| Total income | 183.02 | 141.35 | +29.5% | 192.86 | −5.1% |
| Profit before tax | 39.46 | 26.49 | +49.0% | 47.40 | −16.8% |
| Net profit for the period | 30.45 | 21.18 | +43.8% | 36.67 | −17.0% |
| Attributable to shareholders of the company | 30.71 | 19.73 | +55.7% | — | — |
| EPS, basic (₹) | 6.61 | 4.60 | +43.7% | 7.96 | −17.0% |
| Net margin (%) | 16.9 | 15.3 | 20.9 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 26.99 | 19.82 | +36.2% | 36.81 | −26.7% |
| Other income | 9.55 | 8.39 | +13.8% | 22.19 | −57.0% |
| Total income | 36.54 | 28.21 | +29.5% | 59.00 | −38.1% |
| Profit before tax | 1.39 | 3.59 | −61.3% | 12.69 | −89.0% |
| Net profit for the period | 1.03 | 2.70 | −61.9% | 8.48 | −87.9% |
| EPS, basic (₹) | 0.22 | 0.59 | −62.7% | 1.84 | −88.0% |
| Net margin (%) | 3.8 | 13.6 | 23.0 |
Consolidated
- Filed with BSE
- 27 Jul 2026, 18:22 IST
- Board meeting
- 27 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Jul 2026, 18:22 IST
- Board meeting
- 27 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE